Is nintedanib covered by medical insurance?

Nintedanib (Nintedanib) is a small molecule tyrosine kinase inhibitor (TKI) that binds to a family of growth factor receptors and prevents fibroblast proliferation. It reduces the ongoing fibrotic process and delays the progression to lasting damage. Nintedanib is a tyrosine kinase inhibitor indicated for the treatment and management of idiopathic pulmonary fibrosis, systemic sclerosis-associated interstitial lung disease (SSc-ILD), and interstitial lung disease with a progressive phenotype (ILD).

The original drug of nintedanib has been launched in China, and has entered the scope of Class B medical insurance reimbursement through the relevant regulations of the National Medical Insurance Administration. Patients who meet the above indications can use the national medical insurance for reimbursement. Patients who do not meet the conditions can only purchase this drug at their own expense if they need to use this drug for treatment. Due to different reimbursement ratios in various regions, there may be slight differences in the price after reimbursement. For specific information, please consult local hospitals or medical insurance bureaus.

The active substance in nintedanibnintedanib blocks the activity of some enzymes called tyrosine kinases. These enzymes are present in certain receptors (such as vascular endothelial growth factor, FGF, and PDGF receptors) in lung cells, where they activate several processes related to fibrogenesis. By blocking these enzymes, nintedanib helps reduce the formation of fibrous tissue in the lungs, which helps prevent symptoms of the disease from getting worse. Nintedanib is available by prescription only and is available in capsule form (100 and 150 mg). The recommended dose is 150 mg taken twice daily with food, approximately 12 hours apart. For patients who cannot tolerate this dose, the dose should be reduced to 100 mg twice daily, otherwise treatment should be interrupted.